Rituximab in Treating Patients With Hodgkin's Lymphoma
Trial ID or NCT#
NCT00003820
Status
NOT RECRUITING
Purpose
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
Official Title
Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
Eligibility Criteria
Ages Eligible for Study: Older than 3 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Sarah Daadi
6507256456
View on